Agenus Inc. operates as a publicly traded corporation rather than a wholly acquired subsidiary, meaning it has not been bought out in its entirety by a single corporate buyer. Its equity shares are widely owned and traded publicly on the NASDAQ exchange by institutional investment management firms, mutual funds, corporate insiders, and retail investors. While the company frequently engages in strategic licensing, asset sales, and co-development partnerships with major global pharmaceutical corporations, ownership remains distributed across public markets.